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Receptor activity-modifying proteinThe ﬁrst and third extracellular loops (ECL) of G protein-coupled receptors (GPCRs) have been implicated in
ligand binding and receptor function. This study describes the results of an alanine/leucine scan of ECLs 1 and
3 and loop-associated transmembrane (TM) domains of the secretin-like GPCR calcitonin receptor-like
receptor which associates with receptor activity modifying protein 1 to form the CGRP receptor. Leu195Ala,
Val198Ala and Ala199Leu at the top of TM2 all reduced αCGRP-mediated cAMP production and
internalization; Leu195Ala and Ala199Leu also reduced αCGRP binding. These residues form a hydrophobic
cluster within an area deﬁned as the “minor groove” of rhodopsin-like GPCRs. Within ECL1, Ala203Leu and
Ala206Leu inﬂuenced the ability of αCGRP to stimulate adenylate cyclase. In TM3, His219Ala, Leu220Ala and
Leu222Ala have inﬂuences onαCGRP binding and cAMP production; they are likely to indirectly inﬂuence the
binding site for αCGRP as well as having an involvement in signal transduction. On the exofacial surfaces of
TMs 6 and 7, a number of residues were identiﬁed that reduced cell surface receptor expression, most
noticeably Leu351Ala and Glu357Ala in TM6. The residues may contribute to the RAMP1 binding interface.
Ile360Ala impaired αCGRP-mediated cAMP production. Ile360 is predicted to be located close to ECL2 and
may facilitate receptor activation. Identiﬁcation of several crucial functional loci gives further insight into the
activation mechanism of this complex receptor system and may aid rational drug design.in gene-related peptide; CLR,
, extracellular domain; ECL,
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The calcitonin receptor-like receptor (CLR) is a secretin-like (family
B) G protein-coupled receptor (GPCR) protein that, in association with
receptor activity modifying protein 1 (RAMP1), acts as a receptor for α
and β calcitonin gene-related peptide (CGRP). αCGRP is a potent
vasodilator with important pathophysiological actions especially in
migraine. A structure of the N-termini of CLR and RAMP1 has recently
been published [29]. RAMP1 and CLR dimerization is required for both
ligand binding and cell surface expression [19] and CLR is also known to
form an adrenomedullin receptor when it forms a heterodimer with
either RAMP2 or RAMP3 [19]. A two-step model of receptor activation
has been described for secretin-like GPCRs. Initially the C-terminus of
the peptide ligand binds to the extracellular domain of the receptor.
Then the N-terminus of the ligand associates with the transmembrane(TM) domain of the receptor including the extracellular loops (ECLs),
leading to receptor activation [22]. Broadly, this generic model of
receptor activation is likely to apply to the CGRP receptor although the
important molecular details speciﬁc to αCGRP-binding remain
unknown.
Within GPCRs, the ECLs contribute to receptor afﬁnity and efﬁcacy.
They may also help orientate the TM bundle and provide key molecular
determinants for ligand binding [23]. There is considerable evidence
that the ECLs are important for the binding of peptide agonists to
secretin-like GPCRs but the details may be receptor speciﬁc. Investiga-
tions into the parathyroid hormone 1 (PTH1) receptor using chimeric
receptors and disulﬁde-trapping experiments suggest that the hormone
has a diffuse pharmacophore making contact across all three ECLs, with
the initial N-terminal serine residue positioned between TM5 and TM6
[2,21]. In the glucagon receptor, chimera and mutagenesis experiments
also suggest the peptide is able to make extensive contacts across the
extracellular TM domain, but the N-terminal residues are predicted to
face ECL1 and TM2 [25]. In the secretin receptor, mutagenesis suggests
contacts with ECL1 and ECL2, but a model based on photoafﬁnity cross-
linking places the peptide largely in the vicinity of ECL3 [9,13].
Photoafﬁnity cross-linking data for the binding of GLP-1 suggests that
it binds to ECL2 but closer to ECL1 [20].
The role of the ECLs in the CLR remains elusive. Consequently, an
alanine scan has been used to investigate ECL1 and ECL3 and their
1907J. Barwell et al. / Biochimica et Biophysica Acta 1813 (2011) 1906–1916corresponding TM regions. Endogenous alanine residues within this
region were substituted to leucine residues to probe the signiﬁcance of
the size and/or geometry of their methyl side chains. Mutant receptors
were assessed onmultiple criteria including cAMP production, agonist-
mediated desensitization (which can provide an indirect measure of
β-arrestin association [12]), cell-surface and total expression and
human αCGRP binding in an attempt to determine the functional role
of the residues within the protein.
2. Methods
2.1. Materials
HumanαCGRPwas fromCalbiochem(Beeston,Nottingham,UK). 125I-
iodo8histidyl-human αCGRP was from PerkinElmer Life and Analytical
Sciences (Waltham, MA). [8-3H] Adenosine 3′, 5′, cyclic phosphate, NH4
saltwas fromAmershamBiosciences (Chalfont,UK). Chemicalswere from
Sigma-Aldrich UK. For ELISAs, the primary antibody was mouse, anti-HA
antibodyH9658 [Sigma-Aldrich], the secondaryantibodywasanti-mouse,
horseradishperoxidase conjugated#7076 [Cell SignalingTechnology] and
SIGMAFASTTM o-phenylenediamine tablets were used.
2.2. Expression constructs and mutagenesis
The expression constructs used were human CLR with an N-terminal
hemagglutinin (HA-CLR) epitope tag and human RAMP1 with an
N-terminal myc epitope tag (myc-RAMP1) in pc DNA3.1(–). These
were kindly provided by Dr. S. Foord. HA-CLR mutants were generated
using the QuikChange II site-directed mutagenesis kit (Stratagene,
Cambridge, UK), as described previously [3]. A snake plot showing the
location of the residues mutated and other key features of the
transmembrane domain of CLR is shown in Fig. 1.
2.3. Cell culture and transfection
Cos-7 cells were cultured and transfected with polyethyleneimine
as described previously [27].
2.4. Radioligand binding
Radioligand binding using 125I-iodo8histidyl-human αCGRP on
membranes prepared from transfected Cos-7 cells was as carried out
by centrifugation as described previously [3]. The membrane
concentration was 0.4 mg/ml.Fig. 1. Snake plot of transmembrane domain of CLR. Amino acids of CLR between 125 and 397
regions are shown. Residues that were mutated in the ECL1 and ECL3 regions are shaded.2.5. Assay of cAMP production
48 well plates were transiently transfected withWT receptor (HA-
CLR/myc RAMP1) alongside a mutant receptor in every experiment, to
take account of day-to-day differences in transfection and coupling
efﬁciencies. Stimulation with agonists and assay of cAMP was by a
radioreceptor assay as described elsewhere [27].
2.6. Analysis of cell surface expression of mutants by ELISA and agonist
dependent internalization
24well plates were transiently transfected withWT receptor and a
mutant receptor in every experiment. A negative control of myc
RAMP1/empty pcDNA3.1(−) was used. To measure both cell surface
and total expression of CLR an ELISA was carried out as described
previously [5], but using the antibodies and o-phenylenediamine
tablets described in the Materials section. A Biotek EL800 Universial
Microplate reader using the 490 nm ﬁlter was used to quantify the
peroxidise product. Cell surface expression data was normalized to
make mean WT expression 100% and the mean myc RAMP1/empty
pcDNA3.1(−) vector as 0%. Receptor internalization was measured
after 1 h treatment with 100 nM human αCGRP at 37 °C by the above
cell surface ELISA procedure.
2.7. Total CLR expression
Total WT and mutant receptor expression was only assessed on
mutant receptors that were found to alter cell surface expression. The
ELISA procedure outlined above was conducted but after the
transfected cells were ﬁxed with 3.7% formaldehyde for 15 min, the
cells were permeabilized with 0.1% Triton X-100 in PBS for 1 h.
2.8. Construction of a CLR model to show the ECLs
Two CLR TM domain models were constructed. The putative TM
segments of CLR were aligned against the TM domains in bovine
rhodopsin (inactive, PDB 1U19) and opsin (active, PDB 3DQB) using
the alignment proposed by Vohra and co-workers [30]. Modeller9v5
was used to generate 500 models. The models were ranked by
Modeller9v5 energy objective function. The top 20 structures were
retained and stereochemical quality was assessed by PROCHECKv3.5.4
[16,17]. Based on overall and residue-by-residue geometry a structure
was selected.are depicted as circles containing 1-letter identiﬁers. The putative boundaries of the TM
1908 J. Barwell et al. / Biochimica et Biophysica Acta 1813 (2011) 1906–1916The loop domains were constructed using the program Loopy
[28,31] as described previously [1]. However, ECL2 was divided into
two segments. Cys212 is assumed to participate in a highly conserved
disulphide bond with Cys282. This was used as an anchor region. To
model ECL2, the data of Conner and co-workers was used to select
appropriate conformations [4].
The quality of the loop models was assessed by using the
methodology to model ECL1 and ECL3 of bovine rhodopsin; these
loops were then compared with those found in the crystal structure
1U19. The best ECL1 conformer had a 1.40 Å global root mean squared
deviation from the crystal structure and the best ECL3 conformer had
0.74 Å. Themean andmode of the best top 10 conformers for ECL1 did
not exceed 1.93 Å and 1.54 Å for ECL3.
The ProPka program [18] via the PDBQPR server [7] was used to
assign the protonation states of the titratable groups in each CLR TM
domain model, using the CHARMM parameters set at pH 7.4. The CLR
TM models were then orientated on their Z-axis based on the relative
position of Tyr165 and Tyr367. The CHARMM (c35b3) GBSW module
containing the GB/SA membrane application was used [14]. The all-
atom param22/cmap force-ﬁeld in the presence of a 32 Å implicit
membrane was set up. Then 1500 steps of a steepest descent energy
minimization followed by 5000 steps of adopted basis Newton-
Raphson minimization (or until the root mean squared deviation
[RMSD] was less than 0.001 kcal/mol ) was conducted. TM models
contained an acetylated N-terminus and a N-methylamide C-terminus
to prevent unnecessary large electrostatic attractive forces between
the helical ends during energy minimization.Table 1
The ability of mutant receptors to stimulate cAMP compared to the WT receptor.
Mutant N pEC50 WT pEC50 mutant
ECL1
H194A 5 9.97±0.48 9.41±0.53
L195A 4 10.36±0.25 8.87±0.09⁎⁎
T196A 3 9.73±0.21 10.18±0.10
A197L 4 10.09±0.29 10.05±0.39
V198A 5 9.67±0.17 8.87±0.26⁎
A199L 6 10.20±0.31 8.87±0.32⁎
N200A 3 9.80±0.17 9.62±0.28
N201A 4 9.38±0.16 9.88±0.29
Q202A 4 9.49±0.43 9.17±0.32
A203L 5 9.75±0.22 10.77±0.35⁎
L204A 3 9.73±0.13 9.68±0.17
V205A 4 9.62±0.21 10.04±0.30
A206L 5 9.43±0.29 10.37±0.19⁎
T207A 4 9.98±0.30 10.50±0.20
N208A 3 9.85±0.11 9.97±0.18
ECL3
F349A 4 10.59±0.34 10.72±0.28
V350A 3 9.89±0.02 9.74±0.15
L351A 3 9.36±0.16 9.54±0.04
I352A 6 10.00±0.36 9.33±0.15
P353A 5 9.79±0.27 9.06±0.21
W354A 4 9.08±0.36 8.91±0.28
R355A 4 9.86±0.37 9.55±0.21
P356A 3 10.39±0.42 9.95±0.26
E357A 4 10.44±0.46 8.92±0.39⁎⁎
G358A 3 9.68±0.31 9.46±0.29
K359A 4 9.76±0.12 9.94±0.32
I360A 6 9.26±0.14 8.40±0.22⁎⁎
A361L 7 9.97±0.22 10.27±0.22
E362A 3 9.70±0.26 9.65±0.33
E363A 4 10.32±0.49 9.80±0.32
V364A 3 9.78±0.22 9.94±0.15
Y365A 4 10.20±0.27 10.33±0.25
D366A 3 9.54±0.21 9.72±0.21
Values are pEC50 means±S.E.M. pEC50 mutant values were compared to WT using an inde
⁎ pb0.05.
⁎⁎ pb0.01.
⁎⁎⁎ pb0.001.2.9. Statistical analysis of data
Curve ﬁtting was completed by GraphPad Prism 4 as described
previously [1]. A two-tailed independent t-test was used to determine
signiﬁcance between dose–response curve conditions. The Mann–
Whitney U test was used to determine signiﬁcance between
conditions used in ELISA based assays. The analysis is indicated in
the table and ﬁgure legends and has been described previously [1].3. Results
3.1. Stimulation of cAMP production
Each mutant was challenged with human αCGRP and cAMP
productionwasmeasured (Table 1, Figs. 2 and 3). For ECL1 a reduction
in αCGRP potency (as assessed by signiﬁcant differences in pEC50
values compared to WT receptors) was observed in the mutant
receptors (in the order of the magnitude of EC50 fold decrease);
Leu195Ala (~30 fold), Ala199Leu (~20 fold), Val198Ala (~11 fold),
His219Ala (~11 fold) and Cys212Ala (~9 fold). In contrast, an increase
in αCGRP potency was found in Leu220Ala (~25 fold), Ala203Leu
(~11 fold), Ala206Leu (~9 fold) and Leu222Ala (~6 fold). In ECL3,
Glu357Ala was found to signiﬁcantly decrease pEC50 by ~33 fold
compared to WT; this mutant also showed decreased maximal
responses (41.7%±17.9%). Ile360Ala was also found to signiﬁcantly
decrease pEC50 by ~7 fold compared to WT.Mutant N pEC50 WT pEC50 mutant
P209A 4 9.91±0.33 9.85±0.14
V210A 4 9.95±0.29 10.44±0.23
S211A 4 9.49±0.33 9.60±0.21
C212A 3 9.71±0.28 8.78±0.18⁎
K213A 5 9.49±0.40 8.78±0.39
V214A 4 9.83±0.39 9.97±0.37
S215A 6 9.39±0.33 9.41±0.22
Q216A 3 9.63±0.13 9.94±0.13
F217A 4 9.94±0.43 9.37±0.22
I218A 4 9.27±0.22 9.60±0.25
H219A 3 9.41±0.17 8.35±0.13⁎⁎
L220A 4 9.53±0.17 10.93±0.13⁎⁎⁎
Y221A 4 9.73±0.42 9.01±0.51
L222A 5 9.95±0.21 10.75±0.10⁎
M223A 4 9.71±0.18 9.65±0.15
Y367A 4 9.64±0.21 9.92±0.04
I368A 5 10.13±0.33 10.30±0.22
M369A 4 9.92±0.32 10.53±0.39
H370A 5 9.42±0.14 9.19±0.30
I371A 4 9.96±0.28 10.18±0.20
L372A 3 9.93±0.07 10.08±0.26
M373A 3 10.51±0.28 10.21±0.12
E362A 3 9.70±0.26 9.65±0.33
E363A 4 10.32±0.49 9.80±0.32
V364A 3 9.78±0.22 9.94±0.15
Y365A 4 10.20±0.27 10.33±0.25
D366A 3 9.54±0.21 9.72±0.21
Y367A 4 9.64±0.21 9.92±0.04
I368A 5 10.13±0.33 10.30±0.22
M369A 4 9.92±0.32 10.53±0.39
H370A 5 9.42±0.14 9.19±0.30
I371A 4 9.96±0.28 10.18±0.20
L372A 3 9.93±0.07 10.08±0.26
pendent two-tailed t-test.
Fig. 2. Representative dose–response curves of ECL mutants that showed a signiﬁcant decrease in αCGRP potency for cAMP production. Sigmoidal concentration–response curves
comparing the WT receptor and mutant receptors are shown. Each WT and mutant receptor concentration–response comparison curve is a representative example from at least
three independent experiments. Each assay point was performed in duplicate where each point on the graph represents the mean±S.E.M.
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activity or maximum response. However, in most cases these were
small (Table 2). There were ~40% increases in maximum response for
Leu204Ala and Gln216Ala in ECL1 and for Val350Ala, Arg355Ala,
Ala361Leu and Met369Ala in ECL3. For Leu204Ala and Arg355Ala
there was also a ~30% increase in basal activity; Pro209Ala and
Val210Ala had a similar increase in this parameter.
3.2. Cell surface receptor expression
Expression of receptors was measured using a cell-surface ELISA
(Table 3). Statistically signiﬁcant reductions in cell-surface expressionwere seen in nine mutants in ECL1. The largest reduction in cell
surface expression was with Met223Ala (~40%) but overall the cell
surface reductions seen in thesemutants were fairly modest, although
four consecutive mutants (Phe217Ala, Ile218Ala, His219Ala and
Leu220Ala) reduced cell surface expression. Four mutants in ECL1
were found to increase cell surface expression signiﬁcantly, but the
effect was not much more than a 30% increase (Table 3). By contrast,
in ECL3 there were large decreases in expression for Glu357Ala and
Leu351Ala (N70%). Gly358Ala, Tyr356Ala and Tyr367Ala showed
decreases of around 40%. There were smaller changes in a further
seven mutants (see Table 3). An increase in cell surface expression
was found in His370Ala (of 41%) and Pro353Ala (33%).
Fig. 3. Representative dose–response curves of mutants that showed a signiﬁcant increase in αCGRP potency. Sigmoidal concentration–response curves comparing the WT receptor
andmutant receptors are shown. EachWT andmutant receptor concentration–response comparison curve is a representative example from at least three independent experiments.
Each assay point was performed in duplicate where each point on the graph represents the mean±S.E.M.
Table 3
Cell surface expression of mutant receptors.
Mutant Cell surface
expression (% WT)
Mutant Cell surface
expression (% WT)
ECL1
H194A 106.5±9.9 P209A 133.0±9.0⁎
L195A 92.7±5.4 V210A 111.9±12.4
T196A 96.0±9.2 S211A 92.62±11.6
A197L 88.2±5.3 C212A 69.71±10.3⁎
V198A 133.4±11.6⁎⁎⁎ K213A 94.54±9.1
⁎⁎
1910 J. Barwell et al. / Biochimica et Biophysica Acta 1813 (2011) 1906–19163.3. Total receptor expression
Total receptor expression probing for the HA epitope was assessed
on mutant receptors that were either found to have a signiﬁcantly
different pEC50 and/or cell surface expression. For residues in ECL1, a
signiﬁcant, yet modest, increase in total expression was observed in
Val205Ala and Ala206Leu. A signiﬁcant decrease in total expression
was seen in Cys212Ala and His219Ala but again the size of the effect
was onlymodest (Table 4). For ECL3, a signiﬁcant 44% increase in total
expression compared to WT was observed in Pro353Ala. A signiﬁcantTable 2
Mutant receptors showing large changes in mean basal activity and Emax.
Mutant N Mean basal
activity (% WT)
Mean
Emax (% WT)
ECL1
L204A 3 37.3±18.5 142.3±13.4
P209A 4 41.5±5.2 122.5±5.0
V210A 4 33.7±8.9 117.9±10.7
C212A 3 −6.7±33.3 130.2±23.8
Q216A 3 22.7±8.1 144.0±13.7
M223A 4 13.2±11.1 128.8±16.2
T207A 4 0.4±7.7 122.5±9.3
ECL3
F349A 4 10.3±6.0 122.1±6.8
V350A 3 19.3±5.8 142.3±14.6
I352A 6 25.8±5.3 121.1±8.9
R355A 4 39.7±11.2 151.5±10.9
K359A 4 12.6±14.6 121.7±11.1
A361L 7 15.6±8.2 146.2±12.7
E363A 4 7.6±9.5 127.5±6.5
Y365A 4 22.5±1.3 119.7±6.0
Y367A 4 16.9 ±11.2 123.2±6.0
M369A 4 19.2±6.7 139.5±12.9
TheWT and mutant cAMP dose–response comparison curves were normalized from 0%
to 100% based on WT Top and Bottom values generated by GraphPad Prism 4. The Emax
and basal activity of each mutant was assessed by the mean of the top and bottom of
each dose–response curve. The mutant receptors mean Emax and basal activity was
expressed as a percentage that corresponded to WT normalization. A difference was
noted if the mean size of effect differed by 20% or more. Values reported are mutant
percent means±S.E.M. (% WT).
A199L 130.2±8.2 V214A 88.17±8.9
N200A 74.8±6.0⁎ S215A 101.6±6.8
N201A 91.0±8.3 Q216A 107.3±8.4
Q202A 81.4±11.9 F217A 72.78±6.7⁎
A203L 112.4±6.9 I218A 73.05±8.4⁎⁎
L204A 105.9±5.6 H219A 68.81±7.2⁎⁎⁎
V205A 81.3±3.3 L220A 79.21±6.1⁎
A206L 114.5±4.9⁎⁎ Y221A 107.3±9.9
T207A 111.6±11.5 L222A 94.33±9.6
N208A 68.88±7.3⁎⁎ M223A 58.97±8.3⁎⁎⁎
ECL3
F349A 69.0±7.0⁎ A361L 71.3±11.0
V350A 78.9±5.9 E362A 83.8±5.8⁎
L351A 27.2±4.4⁎⁎⁎ E363A 89.6±11.9
I352A 70.5±4.6⁎⁎⁎ V364A 135.3±18.5
P353A 133.3±11.8⁎⁎ Y365A 60.0±8.7⁎⁎
W354A 88.1±4.7⁎ D366A 85.9±4.9⁎
R355A 66.2±5.5⁎⁎ Y367A 56.6±4.9⁎⁎⁎
P356A 85.0±6.0 I368A 129.0±11.5
E357A 11.0±3.5⁎⁎⁎ M369A 99.9±4.8
G358A 61.4±11.2⁎ H370A 141.1±9.5⁎⁎⁎
K359A 71.8±5.8⁎⁎⁎ I371A 70.5±7.6⁎⁎
I360A 107.7±8.0 L372A 102.3±13.0
Cell surface expression ELISA was used to probe for the presence of the HA epitope.
Mutant HA CLR/myc RAMP1 receptors were compared with WT HA CLR/myc RAMP1
receptors. 3–6 independent experiments that contained triplicate data points were
used in analysis. The raw data for each independent experiment was normalized where
the mean WT receptor cell-surface expression equalled a 100% and the mean negative
control (myc RAMP1/empty pcDNA3.1−) was equal to 0%. Values reported are mutant
means±S.E.M. (% WT). Mutant cell surface expression was compared to WT receptor
using a Mann–Whitney U test.
⁎ pb0.05.
⁎⁎ pb0.01.
⁎⁎⁎ pb0.001.
Table 4
Total expression of mutant receptors.
Mutant Total expression
(% WT mean±S.E.M.)
Mutant Total expression
(% WT mean±S.E.M.)
ECL1
L195A 111.5±8.5 P209A 106.8±5.3
V198A 87.6±13.5 C212A 80.0±7.9⁎
A199L 115.5±5.6 F217A 98.9±6.0
N200A 104.8±7.3 I218A 118.2±12.7
A203L 110.2±8.5 H219A 75.7±16.5⁎⁎⁎
V205A 115.0±4.8⁎ L220A 101.6±4.7
A206L 116.5±3.1⁎⁎ L222A 106.4±6.0
N208A 110.4±3.8 M223A 101.7±6.2
ECL3
L351A 111.0±12.4 I360A 89.5±2.9
I352A 98.9±10.3 A361L 87.2±4.7
P353A 144.0±12.3 ⁎⁎⁎ Y365A 116.0±15.2
W354A 103.5±5.3 D366A 78.2±4.8⁎⁎
R355A 110.9±10.9 I368A 104.1±10.9
E357A 88.6±7.5 H370A 144.3±6.8
G358A 92.9±4.2 I371A 126.9±12.7
Total expression of HA-tagged receptors both mutant and WT were analyzed when co-
transfected with myc RAMP1 using an ELISA. At least 3 independent experiments
containing triplicate data points were used in analysis. Total expression in the mutant
condition was normalized to the WT condition (equal to 100%) and negative control
(myc RAMP1/empty pcDNA3.1− after 0.1% Triton X-100, which was equal to 0%). A
Mann–Whitney U test was used to assess statistical differences between WT and
mutant receptors.
⁎ pb0.05.
⁎⁎ pb0.01.
⁎⁎⁎ pb0.001.
Table 5
Mutant receptors capability of agonist (αCGRP) mediated internalization compared to the WT receptor.
Mutant WT receptor internalization
(% mean±S.E.M.)
Mutant receptor internalization
(% mean±S.E.M.)
Mutant WT receptor internalization
(% mean±S.E.M.)
Mutant receptor internalization
(% mean±S.E.M.)
ECL1
H194A 47.70±4.9 58.14±4.7 P209A 55.38±5.8 55.90±6.3
L195A 53.99±2.8 1.67±3.2⁎⁎⁎ V210A 62.01±4.1 61.18±6.0
T196A 51.98±5.5 67.44±3.2 S211A 54.01±3.1 58.33±2.8
A197L 54.66±2.9 52.04±3.6 C212A 58.04±4.7 37.29±9.7⁎
V198A 55.52±3.0 30.32±3.7⁎⁎⁎ K213A 52.00±4.5 51.53±6.1
A199L 64.04±4.1 8.39±7.7⁎⁎⁎ V214A 46.50±2.9 59.87±5.4
N200A 58.81±3.0 67.90±5.6 S215A 66.03±7.2 64.07±5.1
N201A 56.81±3.9 63.03±2.8 Q216A 50.47±2.5 55.27±3.3
Q202A 60.38±4.9 66.48±8.2 F217A 45.10±8.0 44.78±7.4
A203L 56.37±4.0 62.21±3.3 I218A 48.68±8.5 66.06±9.8
L204A 47.72±5.2 49.54±4.3 H219A 55.42±3.1 75.07±6.9⁎
V205A 51.32±7.4 64.42±4.0 L220A 55.44±3.3 58.27±4.5
A206L 56.97±2.0 61.03±2.2 Y221A 51.50±4.6 63.57±4.1
T207A 53.11±2.1 58.75±10.3 L222A 48.54±7.0 56.60±7.6
N208A 47.87±5.3 65.65±3.1⁎ M223A 48.32±3.2 60.59±4.5
ECL3
F349A 70.16±4.8 62.83±3.5 A361L 78.82±6.7 66.22±10.7
V350A 61.22±8.2 48.00±6.7 E362A 49.11±2.1 58.16±2.3⁎⁎
L351A 57.34±4.0 19.84±7.5⁎⁎⁎ E363A 68.34±4.2 67.59±2.8
I352A 60.98±3.8 55.03±6.2 V364A 68.87±9.2 59.00±7.2
P353A 74.76±1.8 58.80±1.8⁎⁎⁎ Y365A 68.69±4.8 76.69±4.0
W354A 73.25±1.8 57.26±2.7⁎⁎⁎ D366A 48.38±2.6 51.89±5.2
R355A 57.71±6.7 60.95±6.9 Y367A 57.35±4.2 60.54±5.8
P356A 65.78±5.7 76.63±4.8 I368A 64.42±8.3 73.82±3.5
E357A 57.13±3.7 8.589±6.3⁎⁎⁎ M369A 64.77±4.4 67.48±2.8
G358A 60.09±6.7 73.04±10.2 H370A 56.94±6.3 51.04±5.2
K359A 52.46±2.7 59.11±4.7 I371A 56.49±6.0 82.69±3.4⁎⁎
I360A 71.00±2.2 71.55±2.2 L372A 53.99±4.4 62.33±5.4
Agonist mediated internalization of the CGRP receptor (both WT and mutant receptors) was approximated by a HA epitope probing cell surface ELISA taking into account the
difference in cell surface expression levels between CGRP receptors that have or have not been exposed to 100 nM of human αCGRP for an 1 h. Percent mean±S.E.M. agonist
mediated internalization was determined by 3–6 independent experiments that contained triplicate data points. A Mann–Whitney U test was used to compare mutant and WT
percent agonist internalization.
⁎ pb0.05.
⁎⁎ pb0.01.
⁎⁎⁎ pb0.001.
Table 6
Apparent afﬁnities of αCGRP for ECL mutant receptors that show a change in
internalization or pEC50 for cAMP production, estimated by inhibition of radioligand
binding.
Mutant N pIC50 for WT receptor
(mean±S.E.M.)
pIC50 for mutant receptors
(mean±S.E.M.)
ECL1
L195A 5 9.01±0.40 N.M.B.
V198A 4 8.86±0.40 8.07±0.47
A199L 4 8.88±0.25 7.26±0.13⁎⁎
A203L 4 9.33±0.31 9.77±0.64
A206L 5 9.00±0.13 9.19±0.19
N208A 5 9.03±0.09 8.90±0.21
C212A 4 9.04±0.09 6.94±0.49⁎⁎
H219A 4 9.01±0.07 7.91±0.44
L220A 5 9.36±0.20 10.21±0.36
L222A 3 9.84±0.03 10.76±0.17⁎⁎
ECL3
L351A 4 9.04±0.36 N.M.B.
P353A 7 9.18±0.33 8.65±0.24
E357A 3 9.84±0.03 N.M.B
I360A 3 8.77±0.09 7.83±0.33
W354A 4 9.01±0.12 8.75±0.13
E362A 3 9.05±0.04 8.74±0.18
I371A 3 9.84±0.03 10.16±0.11⁎
Mean±S.E.M. pIC50 WT and mutant values shown. An independent two-tailed t-test
was used to assess statistical differences. N.M.B., no measurable binding.
⁎ pb0.05.
⁎⁎ pb0.01.
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Fig. 4. Representative inhibition curves of ECL mutant receptors that signiﬁcantly alter CGRP binding. Sigmoidal αCGRP inhibition curves comparing the WT receptor and mutant
receptors are shown. EachWT andmutant receptor curve is a representative example of at least three independent experiments. Each assay point was performed in duplicate where
each point on the graph represents the mean±S.E.M.
1912 J. Barwell et al. / Biochimica et Biophysica Acta 1813 (2011) 1906–1916but modest decrease (22%) in total expression was observed in
Asp366Ala.
3.4. αCGRP mediated internalization
In ECL1,αCGRPmediated internalization was severely impaired or
abolished in Leu195Ala and Ala199Leu and signiﬁcantly reduced in
Cys212Ala and Val198Ala. In contrast, Asn208Ala and His219Ala were
found to internalize moderately more readily than WT (Table 5).
For ECL3, internalization was severely impaired by Glu357Ala and
signiﬁcantly reduced in Leu351Ala, Pro353Ala and Trp354Ala. In
contrast, Glu362Ala and Ile371Ala were found to internalize more
readily than WT (Table 5).3.5. Inhibition of 125I-αCGRP radioligand binding
The ability of αCGRP to displace 125I-αCGRP was investigated on
mutant receptors that were either found to have a signiﬁcantly
different mean pEC50 and/or agonist-mediated internalization when
compared to WT (see Table 6, Fig. 4). For ECL1, the pIC50 of four
mutants were signiﬁcantly reduced when compared to WT;
Leu195Ala, Ala199Leu, Cys212Ala and His219Ala. In contrast, the
pIC50 of Leu200Ala showed an increase compared toWT. For ECL3, the
mean pIC50 of twomutantswere signiﬁcantly reduced; Leu351Ala and
Glu357Ala. The decrease for Ile360Ala approached signiﬁcance
(p=0.052). Contrastingly, the pIC50 of Ile371Ala showed a small
increase compared to WT.
a b
Fig. 5. Important residues afﬁliated with the TM1–TM2–TM7 region of CLR. a) Side view of the CLR TM domain model generated from bovine rhodopsin (PDB accession code 1U19)
showing the relative position of Leu195, Val198 and Ala199. A transparent ribbon represents the TM helical arrangement, where TM1, 5, 6 and 7 have been labeled. ECL1 and
associated TM2 is highlighted by an opaque ribbon. b) Extracellular view of the CLR TM model (PDB accession code 1U19) represented by transparent ribbon with depth cue
perception. Ile371 is located within TM7. Ala203 and Ala206 are predicted to be in the middle of ECL1. Leu195, Val198 and Ala199 are located at the top of TM2.
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The models of CLR are shown in Figs. 5, 6 and 7. A number of
important features can be noted. In ECL1, Leu195, Val198 and Ala199
residueswhenmutated, impaired normal CGRP receptor pharmacology
but still expressed at the cell surface are predicted to formacluster at the
top of TM2 and are close to the N-terminal segment of ECL2. They are
also close to Ile371 of TM7,which showed enhanced internalization and
a small increase in afﬁnity for αCGRP upon mutation. Ala203 and
Ala206, which on mutation increased αCGRP potency, are predicted to
be at the top of ECL1. His219Ala, Leu220Ala and L222Ala all inﬂuenced
αCGRP efﬁcacy and the residues are predicted to be located in the
middle of TM3. Leu351Ala, Arg355Ala, Glu357Ala, Gly358Ala,
Lys359Ala, Glu362Ala, Tyr365Ala, Tyr367Ala and Ile371Ala werea
Fig. 6. Predicted location of H219, L220, L222 and I360. a) Side view of the CLR TM domain
transparent ribbon. TM3, ECL3 and ECL2 are opaque ribbons. His219, Leu220 and Leu22
b) Extracellular view of the CLR TM model. ECL2 is transparent. The same residues as abovfound to decrease cell surface expression and they are all predicted to
be located across TM6, ECL3 and TM7. These residues are predicted to
face outwards toward the supposed lipid environment (Fig. 7).4. Discussion
Currently, it is unclear how extracellular loops in Secretin-like GPCRs
contribute to receptor functioning. A systematic alanine/leucine scanwas
conducted on ECL1 and ECL3 of CLR and their corresponding juxtamem-
brane regions. Mutant CGRP receptors were assessed on multiple criteria
including; cAMP accumulation, cell surface expression, total expression,
agonist mediated internalization and αCGRP radioligand binding.
This approach found that both regions of the receptor are required forb
model generated from bovine rhodopsin (PDB accession code 3DQB) represented by
2 are located within TM3. Ile360 is located within ECL3 in close proximity to ECL2.
e are shown.
Fig. 7. Putative RAMP1 interface. Side view of the CLR TM domain model generated from bovine rhodopsin (PDB accession code 3DQB) represented by transparent ribbons. TM6 and
TM7 highlighted by opaque ribbons. The side chains of Leu351, Arg355, Gly358, Lys359, Glu362, Tyr365, Tyr367 and Ile357 are highlighted to represent residues that were found to
reduce cell surface expression and predicted in this model to face outward toward the supposed lipid environment.
1914 J. Barwell et al. / Biochimica et Biophysica Acta 1813 (2011) 1906–1916normal receptor pharmacology and has revealed key molecular de-
terminants that facilitate receptor activation.
A cluster of three residues, Leu195, Val198 and Ala199 that are
located at the top of TM2 and predicted to face into the TM bundle
(Fig. 5) are required for CGRP receptor function. Both Leu195 and
Ala199 disrupted CGRP binding when mutated, thereby providing a
likely explanation of their effects. Leu195 and Ala199 may directly
participate in the orthosteric binding site or the mutations could
indirectly impair αCGRP binding (e.g. disrupt helical packing or
water–lipid interface). The hydrophobic triplet cluster is predicted to
be between TM1, 2 and 7. Within rhodopsin-like GPCRs, this region of
the receptor has been termed the “minor groove” when considering
ligand binding and it has been suggested that it is important for
activation, particularly of beta-arrestin [24]. Interestingly Ile371,
which is predicted to be in close proximity to the groove, increased
CGRP receptor internalization when mutated to alanine, possibly
reﬂecting better association of the receptor with β-arrestin. It is not
known if a minor groove exists in secretin-like GPCRs, but there is
evidence that the region is important. In the family B receptors, the
consensus residue at Leu195 is actually an aspartate, which is part of a
Lys/ArgGluArg motif found in 10/15 of human secretin-like GPCRs
(Supplementary Fig. 1). Langer et al., [15] found that mutating this
motif reduced the ability of the VPAC1 receptor to stimulate cAMP
production. This observation is in line with previous studies on the
VPAC1 receptor [10] and the secretin receptor [6]. Although primary
sequence is not conserved, these observations support the importanceof this region in secretin-like GPCRs. There is evidence that small-
molecule calcitonin agonists interact with residues at the exofacial
end of TM1 [8]. This again suggests the plausibility of a molecular
switch necessary for activation within this region of the receptor.
Within ECL1 itself, Ala203Leu and Ala206Leuwere found to increase
the potency ofαCGRP in its ability to stimulate cAMP. It is plausible that
the introduced leucines assist αCGRP docking into the TM domain,
although the mechanism behind this is unknown. At the very base of
ECL1, mutation of Cys212 severely impaired receptor function,
consistent with its involvement in a disulﬁde bond with C282 located
in ECL2; a highly conserved feature of all GPCRs.
A cluster of three residues is predicted to be located in the middle
of TM3 (Fig. 6). His219Ala reduced total and cell surface expression
and cAMP production. However the receptor showed a small increase
in agonist mediated internalization, possibly suggesting an increase in
coupling to β-arrestin. Leu220Ala and Leu222Ala increased the
potency of αCGRP in stimulating cAMP production and Leu222Ala
was found to signiﬁcantly enhance αCGRP binding. In rhodopsin-like
GPCRs, TM3 is crucial for receptor activation and these residues may
deﬁne a portion of the helix that is important for mediating
conformational changes in CLR [32]. Models of CLR based on different
activity states of rhodopsin suggested that TM3 in CLR might undergo
a subtle rotational movement upon activation, which changes the
relative positions of His219, Leu220 and Leu222. This is very
speculative, but given that there are some shared features in the
activation mechanisms of rhodopsin- and secretin-like GPCRs [3,26],
1915J. Barwell et al. / Biochimica et Biophysica Acta 1813 (2011) 1906–1916this cluster of residues is in an excellent position to take part in inter-
helical interactions. Yet, it cannot be ruled out that αCGRP may
directly inﬂuence this cluster of residues. Cross-linking data indicates
that the N-terminus of PTH is in close proximity to Phe424 of the PTH1
receptor [21]; in our model of CLR, the equivalent to this residue
(Ile352, discussed below), is at a similar level in the helical bundle to
Leu220 (see Supplementary Fig. 2). Thus it remains plausible that
αCGRP may penetrate deep within the juxtamembrane domain.
Within the predicted ECL3 (Fig. 7), Ile360Ala had major effects on
CGRP potency. This is predicted to be in the center of ECL3, in close
proximity to ECL2. It signiﬁcantly reduced cAMP production. It is
reasonable to speculate that Ile360 contributes either directly to the
signal transduction process mediated by αCGRP or participates
indirectly by stabilizing ECL2.
Half of the mutants in ECL3 and the associated juxtamembrane
regions reduced cell surface expression of the CGRP receptor but had no
effect on total receptor expression. Glu357 in ECL3 and Leu351, deep in
TM6, are particularly important for normal CGRP receptor cell surface
expression. Experimental evidence has shown that RAMP3 dimerized
with the secretin receptor at TM6 and TM7 [11]; a result consistentwith
an earlier prediction from evolutionary trace analysis [30]. Most of the
residues,whichwere found tohaveadecrease in cell surfaceexpression,
are predicted to be located across TM6, ECL3 and TM7 with their side-
chains facing outwards toward the lipid environment (Fig. 7), although
some intra-helical packing effects cannot be ruled asGlu357 is predicted
in the inactivemodel to associatewith TM5. Themodeling is speculative
as the rhodopsin template used for this is not truly representative,
althoughwe have used it to successfully predict the effects ofmutations
in TM6 [3]. However, given these limitations, the model predicts the
mutations identiﬁed could theoretically participate in a RAMP1
interface disrupting the efﬁciency of CLR and RAMP1 dimerization.
RAMP1 is a chaperone protein and its association to CLR is essential for
CGRP receptor trafﬁcking to the cell surface [19].
Given thatmovements of TM6 are needed for GPCR activation [3,32]
it is interesting that a cluster of residues at the TM6–TM7 interface
(Ile352Ala, Arg355Ala, Lys359Ala, Tyr365Ala and Tyr367Ala) are
associated with increases in either basal activity or maximum response
onmutation.Within the PTH receptor, Leu368, Tyr421 and Phe424 have
been shown to be in close proximity to the N-terminus of bound PTH
[21] and so may be involved in agonist-mediated conformational
changes; Phe424 of the PTH receptor is the equivalent of Ile352 of CLR.
Given the increase in basal activity it is possible that these residuesmay
help constrain an inactive receptor conformation. This effect may be
mediated by intra-helical packing within the CLR or via RAMP1
interactions. This adds to earlier work showing that TM6 of CLR is
needed for CGRP receptor signal transduction [3].
In conclusion, it is clear that both ECL1 and ECL3 of CLR are essential
in the normal functioning of the CGRP receptor. Novel molecular
determinants havebeen found that enhanceand impair both the afﬁnity
and efﬁcacy of the receptor. Within ECL1 and its associated TM regions
are key residues that regulate both the binding and the efﬁcacy of
αCGRP. ECL3 and its associated TM domains are important for cell
surface receptor expression, possibly by promoting RAMP1 association.
Furthermore there are also individual residues, which contribute to
recognition of αCGRP and its efﬁcacy. It remains to be shown whether
residues within the loops are in direct contact with αCGRP. This study
will aid further efforts to probe the extracellular surface of the CGRP
receptor alongwith RAMP1/CLR interface and guide future experiments
to map out the large diffuse pharmacophore of αCGRP.
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